$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which company is developing and producing Erdafitinib and its global launch status?
2026-02-01 22:25:32
Check Details
The latest official instructions for Erlotinib (Loret) cover usage, dosage and precautions
2026-02-01 22:25:32
Check Details
A complete analysis of the main efficacy, mechanism of action and scope of indications of tofacitinib (Shangjie)
2026-02-01 22:25:32
Check Details
Reasonable standard usage and dosage of cycloserine in different patients and different disease stages
2026-02-01 22:25:32
Check Details
Is linezolid (Siwo) in tablet form and what are the differences in use between different dosage forms?
2026-02-01 22:25:32
Check Details
Summary of the differences in efficacy between ribociclib (Calilon) and palbocicillin in the combined or comparative treatment of breast cancer
2026-02-01 22:25:32
Check Details
Is cemiplimab an immune drug or a targeted drug and an in-depth analysis of its PD-1 inhibition mechanism
2026-02-01 22:25:32
Check Details
Which class of drugs does Daprodustat belong to and its position and characteristics among HIF-PH inhibitors?
2026-02-01 22:25:32
Check Details
Is durvalumab (durvalumab) an immunological drug or a targeted drug and analysis of its mechanism
2026-02-01 22:25:32
Check Details
Which company is developing and producing Zolbetuximab and its global launch and supply status?
2026-02-01 22:25:32
Check Details
Key contents of the official instruction manual of EIKANCE 0.01% Atropine Sulfate Eye Drops, including usage, dosage and contraindications
2026-02-01 22:25:32
Check Details
Telisotuzumab-EMRELIS complete Chinese instruction manual, including indications, usage and precautions
2026-02-01 22:25:32
Check Details
1
2
...
2422
2423
2424
2425
2426
2427
2428
...
10214
10215
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
ROS and Cancer: The Potential of Natural Antioxidants
2
LONSURF® (Trifluridine/Tipiracil): Unveiling the Global R&D and Supply Chain Behind the Oral Chemotherapy
3
Breaking the Bottleneck: KOSELUGO® (Selumetinib) Reshapes the Treatment Landscape for Neurofibromatosis Type 1 (NF1)
4
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
5
Niraparib: A PARP Inhibitor for Ovarian Cancer Maintenance Therapy
6
Abiraterone Acetate: CYP17 Inhibitor for Advanced Prostate Cancer
7
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation
8
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
9
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
10
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
11
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
12
Adagrasib Medication Management Guide for Special Populations